Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer

Xiaolong Tang1, Yahang Liang1, Guorui Sun1, Qingsi He1, Zhenyu Hou1, Xingzhi Jiang1, Peng Gao2 and Hui Qu1

© The Author(s) 2022

Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients. There is therefore an urgent need to identify potential targets for reversing chemotherapy resistance in GC patients. In this study, we analyzed the tumor samples of GC patients who received neoadjuvant chemotherapy based on oxaliplatin through quantitative proteomics and identified the potential chemoresistance-related protein cellular retinoic acid binding protein 2 (CRABP2). CRABP2 was significantly upregulated in the tumor tissues of chemoresistant GC patients and was closely related to prognosis. The results of cell function experiments showed that CRABP2 can promote the oxaliplatin resistance of GC cells in vitro. Coimmunoprecipitation and GST pulldown assays showed that CRAPB2 expedited the binding of BAX and PARKIN in GC cells and facilitated the ubiquitination-mediated degradation of BAX. Furthermore, both the in vitro assay and cell-derived xenograft (CDX) in vivo model verified that CRABP2 promoted oxaliplatin resistance by inhibiting BAX-dependent cell apoptosis. Further experiments proved that the abnormally high expression of CRABP2 in oxaliplatin-resistant GC cells was affected by TET1-mediated DNA hydroxymethylation. The patient-derived xenograft (PDX) model suggested that interference with CRABP2 reversed oxaliplatin resistance in GC in vivo. In conclusion, the results of our study show that CRABP2 was a key molecule in oxaliplatin resistance regulation and could be a new target for reversing the chemoresistance of GC.

Cell Death and Disease (2022)13:848 ; https://doi.org/10.1038/s41419-022-05299-2

INTRODUCTION
Gastric cancer (GC) is one of the most frequent cancer types and the second most common cause of cancer-related deaths in the world. The incidence of GC is particularly high in east Asia, eastern and southern Europe, and parts of central and south America [1]. Although surgery is the primary treatment for GC, a considerable number of patients are diagnosed at advanced stages, with a 5-year survival rate of <50% [2]. Multimodality strategies are being used to improve survival in GC patients. Currently, chemotherapy is routinely used for the management of patients with advanced-stage GC. Among the various chemotherapy regimens available for GC patients, oxaliplatin (OXA) is a fundamental drug [3]. OXA is a DNA alkylating agent that causes cell death by inducing endogenous apoptosis [4]. However, a considerable proportion of GC patients do not respond well to chemotherapy [5], and the molecular mechanism of OXA resistance is still unclear. Therefore, there is an urgent need to clarify the molecular mechanism of OXA resistance in GC patients.

Focusing on a cohort of GC patients who received neoadjuvant chemotherapy before surgery, we used quantitative proteomics and identified cellular retinoic acid binding protein 2 (CRABP2), which was significantly upregulated in chemotherapy-resistant GC tissues. CRABP2 was related to the poor prognosis of GC patients and promoted OXA resistance in GC cells. Moreover, CRABP2 promoted oxaliplatin resistance in vitro and in vivo. The coimmunoprecipitation and GST pulldown assays showed that CRABP2 could directly bind to apoptosis regulator BAX (BAX) and E3 ubiquitin-protein ligase parkin (PARKIN) in GC cells and facilitated the ubiquitination degradation of BAX. Furthermore, CRABP2 promoted OXA resistance by inhibiting BAX-dependent cell apoptosis in vitro and in vivo, and the expression of CRABP2 was affected by TET1-mediated DNA hydroxymethylation. The patient-derived xenograft (PDX) model suggested that interference with CRABP2 reversed the OXA resistance of GC in vivo. Our study identified the important role of CRABP2 in OXA resistance and could be a potential target for reversing chemoresistance in GC patients.

RESULTS
CRABP2 was upregulated in chemotherapy-resistant GC patients
To search for chemotherapy resistance-related proteins in GC patients, we first obtained tumor tissue samples from GC patients after neoadjuvant chemotherapy (NAC) and divided the patients into a chemotherapy-sensitive (CS) group and a chemotherapy-resistant
upregulated (log2 FC = 1.89). Moreover, the expression levels of CRABP2 were significantly upregulated in the tissues of CR patients (Fig. 1d, e). As the patients enrolled in this study received the SOX (oxaliplatin plus fluorouracil) regimen, to specify which drug CRABP2 was mainly affected, we overexpressed CRABP2 and conducted a CCK-8 assay. The results showed that overexpression of CRABP2 expedited the binding of BAX and PARKIN in GC cells (Fig. 4) and that cell apoptosis increased significantly (Fig. 4d), which indicates that OXA mainly induced oxaliplatin resistance. In AGS cells, the expression of cleaved caspase 3 (CC3) increased (Fig. 4f), and OXA triggered apoptosis of the AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 promoted the binding of BAX and PARKIN, the formation of the proteasome in AGS cells after knocking down or overexpressing CRABP2 was blocked, BAX and PARKIN were pulled down by the GST-CRABP2 fusion protein-bound beads but not with control beads by SDS–PAGE analysis, indicating the physical interaction of CRABP2 and BAX/PARKIN (Fig. 3c). These findings indicated that CRABP2 can directly interact with BAX and PARKIN. Moreover, we performed co-IP assays and western blotting to verify the interaction between BAX and CRABP2 and between PARKIN and CRABP2 (Fig. 3d). To further confirm the interaction, we interfered with the expression of CRABP2 in AGS cells, and the binding ability of BAX to PARKIN decreased (Fig. 3e). However, the binding ability of CRABP2 to PARKIN in AGS cells was not affected by the expression of BAX (Fig. 3f), and the binding ability of CRABP2 to BAX in AGS cells was not affected by the expression of PARKIN (Fig. 3g). Furthermore, immunofluorescence experiments showed the common subcellular locations of CRABP2/BAX/PARKIN proteins in both AGS and HGC-27 cells (Fig. 3h, i). These results showed that CRABP2 can be independently combined with BAX and PARKIN. PARKIN is a protein that activates E3 ubiquitin-protein ligase activity [6]. To verify whether the combination of PARKIN and BAX promoted the degradation of BAX, we overexpressed CRABP2 in AGS cells and treated cells with cycloheximide (CHX) for 0, 2, 4, 6, 8, or 10 h. The results suggested that the half-life of the BAX protein decreased significantly (Fig. 3j). In AGS cells with CRABP2 knockdown, CHX showed the opposite effects (Fig. 3k). In summary, these results showed that CRABP2 promoted the degradation of BAX by expediting the binding of BAX and PARKIN in GC cells.

CRABP2 facilitated the ubiquitination degradation of BAX and induced oxaliplatin resistance

To further study the molecular mechanism of BAX degradation, we used MG-132 (Z-Leu-Leu-Leu-al, a proteasome inhibitor) to block the formation of the proteasome in AGS cells after knocking down or overexpressing CRABP2. The results of Co-IP and western blotting confirmed that CRABP2 could promote the ubiquitination degradation of BAX (Fig. 4a). To study the specific mechanism by which CRABP2 promotes BAX ubiquitination degradation, we interfered with/overexpressed the expression of CRABP2 and transfected HA-labeled ubiquitinated plasmids at different sites. Then, we carried out a Co-IP experiment of HA. The results confirmed that CRABP2 affects the ubiquitination of BAX at the 48th lysine residue (Lys48) (Fig. 4b). After adding OXA to AGS/HGC-27 cells, the activity of caspase 9 was significantly upregulated (Fig. 4c), but the activity of caspase 12 did not change significantly (Fig. 4d), which indicates that OXA mainly affected the mitochondrial apoptotic pathway. After adding OXA to AGS/HGC-27 cells, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h). Moreover, after knocking down or overexpressing CRABP2, the expression of cleaved caspase 3 (CC3) was upregulated (Fig. 4e). Moreover, after adding OXA to AGS and HGC-27 cells, the expression of DNA damage/repair-related proteins increased (Fig. 4f), and OXA triggered apoptosis of the mitochondrial pathway caused by BAX (Fig. 4g). After CRABP2 knockdown/overexpression in AGS/HGC-27 cells, the activity of caspase 9 changed significantly (Fig. 4h).
Fig. 1 The expression of CRABP2 was upregulated in chemoresistant GC patients and predicted prognosis. a Typical image examples of CR and CS gastric cancer patients who received NAC. The volcano map (b) and heatmap (c) of the most upregulated/downregulated differentially expressed proteins in CR and CS tumor tissues. The qRT–PCR (d, n = 22) and western blotting (e, n = 4) results showed the expression of CRABP2 in tumor tissues of CR and CS patients. The CCK-8 results of AGS cells treated with OXA or fluorouracil (g) after knockdown/overexpression of CRABP2. h The relative expression of CRABP2 in parental and OXA-resistant GC cells by qRT–PCR. i The expression of CRABP2 from the TCGA database (tumor = 335; normal = 26). Mann–Whitney U test (Wilcoxon rank sum test). The outlier values (median±2 IQR) and extreme values (median ± 3.5 IQR) were excluded. IQR: interquartile range. The expression of CRABP2 in tumor tissues and adjacent normal tissues of GC patients by qRT–PCR (j, n = 44) and western blotting (k, n = 12). l Typical IHC images of CRABP2-positive and CRABP2-negative tumor tissues. m The correlation curves between CRABP2 expression and OS of GC patients (n = 488). (CR chemotherapy resistance, CS chemotherapy sensitivity, OXA oxaliplatin, C tumor tissue, N normal tissues, IHC immunohistochemistry, OS overall survival). *P < 0.05, **P < 0.01, ***P < 0.001.
down CRABP2, the expression levels of cleaved caspase 3 (CC3) were upregulated in both AGS and HGC-27 cells, while over-expressing CRABP2 led to the opposite results (Fig. 4i). To verify the effects of CRABP2 on OXA resistance, we added OXA to AGS and HGC-27 cells and knocked down/overexpressed CRABP2. The results suggested that CRABP2 can inhibit the activation of the P53-BAX apoptosis pathway induced by OXA (Fig. 4j). Moreover, after adding OXA to AGS/HGC-27 cells and overexpressing CRABP2, the apoptosis of the mitochondrial pathway triggered by OXA was inhibited, and vice versa (Fig. 4k, l). These results suggested that CRABP2 can inhibit cell apoptosis caused by the mitochondrial BAX-dependent pathway and induce oxaliplatin resistance in GC.

CRABP2 promoted oxaliplatin resistance by inhibiting BAX-dependent cell apoptosis

Previous experiments suggested that CRABP2 inhibited BAX-dependent cell apoptosis caused by OXA. To verify the oxaliplatin resistance mechanisms of CRABP2, we performed experiments in vitro and in vivo. After knocking down CRABP2 and BAX simultaneously, the increased percentage of apoptotic cells caused by knocking down CRABP2 was restored (Fig. 5a), the activity of caspase 9 was restored (Fig. 5b), and the expression of cleaved caspase 3 was restored (Fig. 5c). These results suggest that the cell apoptosis inhibition of CRABP2 depends on BAX in vitro. To perform the in vivo experiments, we constructed a cell-derived xenograft (CDX) model. First, lentiviruses overexpressing CRABP2 or BAX (named oe-CRABP2 or oe-BAX, respectively) were used to infect HGC-27 cells. Then, forty nude mice were randomly divided into four groups (NC + PBS, oe-CRABP2 + OXA, oe-CRABP2 + oe-BAX + OXA, and NC + OXA) and were administered different treatments (see the Methods section and Fig. 5d). Finally, all mice were euthanized, and the tumors were removed and measured (Fig. 5e). The weight and volume of tumors from the four groups of CDX mice suggested that after overexpressing CRABP2 and BAX simultaneously, the increased chemoresistance ability of HGC-27 cells caused by overexpressing CRABP2 was reversed (Fig. 5f, g). Half of the tumors were used to examine the expression of CRABP2 and BAX in tumors from different groups by western blotting (Fig. 5h), and the other half of the tumors were examined with HE and IHC staining (Fig. 5i). The results showed that CRABP2 promoted oxaliplatin resistance through the BAX-dependent cell apoptosis pathway.

CRABP2 promoted oxaliplatin resistance by inhibiting BAX-dependent cell apoptosis

Previous experiments suggested that CRABP2 inhibited BAX-dependent cell apoptosis caused by OXA. To verify the oxaliplatin resistance mechanisms of CRABP2, we performed experiments in vitro and in vivo. After knocking down CRABP2 and BAX simultaneously, the increased percentage of apoptotic cells caused by knocking down CRABP2 was restored (Fig. 5a), the activity of caspase 9 was restored (Fig. 5b), and the expression of cleaved caspase 3 was restored (Fig. 5c). These results suggest that the cell apoptosis inhibition of CRABP2 depends on BAX in vitro. To perform the in vivo experiments, we constructed a cell-derived xenograft (CDX) model. First, lentiviruses overexpressing CRABP2 or BAX (named oe-CRABP2 or oe-BAX, respectively) were used to infect HGC-27 cells. Then, forty nude mice were randomly divided into four groups (NC + PBS, oe-CRABP2 + OXA, oe-CRABP2 + oe-BAX + OXA, and NC + OXA) and were administered different treatments (see the Methods section and Fig. 5d). Finally, all mice were euthanized, and the tumors were removed and measured (Fig. 5e). The weight and volume of tumors from the four groups of CDX mice suggested that after overexpressing CRABP2 and BAX simultaneously, the increased chemoresistance ability of HGC-27 cells caused by overexpressing CRABP2 was reversed (Fig. 5f, g). Half of the tumors were used to examine the expression of CRABP2 and BAX in tumors from different groups by western blotting (Fig. 5h), and the other half of the tumors were examined with HE and IHC staining (Fig. 5i). The results showed that CRABP2 promoted oxaliplatin resistance through the BAX-dependent cell apoptosis pathway.

**Table 1.** Correlation between CRABP2 expression and the clinicopathological characteristics of GC patients.

| Variables                  | No. of patients | CRABP2 expression | $\chi^2$ | P value |
|----------------------------|-----------------|-------------------|----------|---------|
| Age (year)                 |                 |                   |          |         |
| $\leq$60                   | 208             | Positive 89 (42.79) | 0.00     | 0.949   |
|                            |                 | Negative 119 (42.5) |          |         |
| $>$60                      | 280             | Positive 119 (57.21)| 0.03     | 0.853   |
|                            |                 | Negative 161 (57.5) |          |         |
| Sex                        |                 |                   |          |         |
| Male                       | 397             | Positive 170 (81.73)| 12.97    | 0.000   |
|                            |                 | Negative 227 (81.07)|          |         |
| Female                     | 91              | Positive 38 (18.27)| 0.04     | 0.526   |
|                            |                 | Negative 53 (18.93)|          |         |
| Tumor diameter (cm)        |                 |                   |          |         |
| $\leq$5                    | 349             | Positive 131 (62.98)| 0.03     | 0.853   |
|                            |                 | Negative 218 (77.86)|          |         |
| $>$5                       | 139             | Positive 77 (37.02)| 0.04     | 0.526   |
|                            |                 | Negative 62 (22.14)|          |         |
| Surgical type              |                 |                   |          |         |
| Subtotal gastrectomy       | 381             | Positive 157 (75.48)| 3.44     | 0.064   |
|                            |                 | Negative 224 (80)  |          |         |
| Total gastrectomy          | 107             | Positive 51 (24.52)| 0.03     | 0.853   |
|                            |                 | Negative 56 (20)   |          |         |
| Tumor differentiation      |                 |                   |          |         |
| Poor                       | 272             | Positive 126 (60.58)| 1.42     | 0.233   |
|                            |                 | Negative 146 (52.14)|          |         |
| Well/Moderate              | 216             | Positive 82 (39.42)| 12.97    | 0.000   |
|                            |                 | Negative 134 (47.86)|          |         |
| pT stage                   |                 |                   |          |         |
| T1-3                       | 263             | Positive 101 (48.56)| 4.15     | 0.042   |
|                            |                 | Negative 162 (57.86)|          |         |
| T4                         | 225             | Positive 107 (51.44)| 0.70     | 0.400   |
|                            |                 | Negative 118 (42.14)|          |         |
| pN stage                   |                 |                   |          |         |
| N0                         | 224             | Positive 81 (38.94)| 3.44     | 0.064   |
|                            |                 | Negative 143 (51.07)|          |         |
| N+                         | 264             | Positive 127 (61.06)| 7.07     | 0.008   |
|                            |                 | Negative 137 (48.93)|          |         |
| pTNM stage                 |                 |                   |          |         |
| I–II                       | 276             | Positive 100 (48.08)| 10.61    | 0.001   |
|                            |                 | Negative 176 (62.86)|          |         |
| III                        | 212             | Positive 108 (51.92)| 2.94     | 0.086   |
|                            |                 | Negative 104 (37.14)|          |         |
| Lymphovascular invasion    |                 |                   |          |         |
| Present                    | 93              | Positive 47 (22.6)| 2.94     | 0.086   |
|                            |                 | Negative 46 (16.43)|          |         |
| Absent                     | 395             | Positive 161 (77.4)| 0.04     | 0.526   |
|                            |                 | Negative 234 (83.57)|          |         |

All P values < 0.05 are indicated in bold print.
reduced the tumor size (Supplementary Fig. 5f), volume (Supplementary Fig. 5g) and weight (Supplementary Fig. 5h). The expression of BAX/PARKIN was examined by western blotting (Supplementary Fig. 5i) and IHC (Supplementary Fig. 5j).

The expression of CRABP2 was affected by TET1-mediated DNA hydroxymethylation

Preliminary experiments showed that the expression of CRABP2 was significantly upregulated at the mRNA level in OXA-resistant GC cells compared with parental cells (Fig. 1h). Therefore, we verified the effects of epigenetic modification on the expression of CRABP2. After adding 5AZ (DNA methylase inhibitor, 5 mM), Bobcat339 (DNA hydroxymethylase inhibitor, 1 mM), D2NEP (histone methylase inhibitor, 5 mM), TSA (histone deacetylase inhibitor, 2 mM), SAHA (histone deacetylase inhibitor, 2 mM) to AGS and HGC-27 cells for 48 h, the mRNA expression changes in CRABP2 were detected. The results confirmed that CRABP2 was sensitive to methylated and hydroxymethylated modifications (Fig. 6a). We further examined the methylation/hydroxymethylation level of OXA-resistant GC cells and parental GC cells and found that the methylation level of OXA-resistant cells decreased (Fig. 6b), while the level of hydroxymethylation increased (Fig. 6c).

After that, we detected the expression and activity of DNA methylase, demethylase, and hydroxymethylase from the OXA-resistant and parental GC cells and found that the expression levels of methylase and demethylyase did not change significantly (Fig. 6d), while that of the hydroxymethylase TET1 was enhanced (Fig. 6d, e). Next, we used Methyl Primer Express v1.0 (https://products.appliedbiosystems.com) to predict and design the methylation sites in the promoter region of CRABP2 (Fig. 6f) and performed ChIP experiments using a TET1 antibody. The results confirmed that TET1 can be enriched in the promoter region of CRABP2 (Fig. 6g). The results of the hydroxymethylated ChIP assay also confirmed that there is a hydroxymethylated modification in the promoter region of CRABP2 (Fig. 6h). After knocking down or overexpressing TET1, the expression of CRABP2 was affected by TET1/BAX/CRABP2 was examined by western blotting (Supplementary Fig. 6d). The in vivo experiments showed that knocking down/overexpressing TET1 significantly affected the tumor size (Supplementary Fig. 6e), volume (Supplementary Fig. 6f) and weight (Supplementary Fig. 6g). The expression of TET1/BAX/CRABP2 was examined by western blotting (Supplementary Fig. 6h).

Interference with CRABP2 reversed the oxaliplatin resistance of GC in vivo

To further confirm the significance of CRABP2 in mediating oxaliplatin resistance in GC in vivo, we constructed a GC patient-derived xenograft (PDX) model (Fig. 7a). The details of the PDX model construction are shown in the Methods section. In brief, the tissues from tumors of GC patients were transplanted subcutaneously into the right axilla of mice and treated with OXA. The largest xenografts (indicating the most resistant to OXA) were isolated and transplanted subcutaneously into the right axilla of

| Table 2. Univariate and multivariate analysis of factors associated with overall survival in GC patients. |
|----------------|-----------------|-----------------|
| Overall survival | HR (95% CI)     | P value         |
| Univariate analysis |                 |                 |
| Age (<60 years vs. >60 years) | 1.24 (0.9–1.7) | 0.190 |
| Sex (male vs. female) | 0.66 (0.43–1.02) | 0.059 |
| Tumor diameter (<5 cm vs. >5 cm) | 1.11 (0.79–1.55) | 0.545 |
| Surgical type (subtotal gastrectomy vs. total gastrectomy) | 1.23 (0.9–1.68) | 0.198 |
| Tumor differentiation (poor vs. well/moderate) | 0.9 (0.63–1.28) | 0.545 |
| pT stage (T1–3 vs. T4) | 1.02 (0.68–1.52) | 0.936 |
| pN stage (N0 vs. N+) | 1.98 (0.94–4.19) | 0.073 |
| pTNM stage (I–II vs. III) | 3.71 (1.77–7.8) | 0.001 |
| Lymphovascular invasion (present vs. absent) | 0.72 (0.51–1.01) | 0.054 |
| CRABP2 expression (negative vs. positive) | 1.41 (1.01–1.98) | 0.043 |

All P values < 0.05 are indicated in bold print.
another mouse for the second-generation PDX model. Then, we constructed in vivo-grade siRNAs of CRABP2. After treatment with OXA and local injection of siRNAs, the mice were euthanized, and the tumors were removed and measured (Fig. 7b). We weighed the tumors and calculated the tumor volume of each group of mice (P < 0.001, Fig. 7c, d). The expression of CRABP2 and BAX was measured by western blotting (Fig. 7e). Tumor specimens were treated with formalin, embedded in paraffin and then examined via HE and IHC staining (Fig. 7f). The results suggested that the abnormally high expression of CRABP2 is affected by TET1-mediated...
DNA hydroxymethylation and promotes the ubiquitination of BAX by enhancing the binding of BAX and PARKIN, inhibiting cell apoptosis under oxaliplatin treatment (Fig. 7g).

**DISCUSSION**

Gastric cancer (GC) is one of the most common malignant tumors of the digestive system worldwide. Although surgery is the main treatment for GC, most patients still need chemotherapy to improve their prognosis [7]. Currently, chemotherapy is routinely used as an adjuvant treatment after surgery for GC patients [8]. In recent years, many scholars have recommended preoperative chemotherapy for advanced GC patients, which is called neoadjuvant chemotherapy (NAC) [9]. However, regardless of whether postoperative or preoperative chemotherapy is used, a considerable number of GC patients do not respond well, and the molecular mechanism of chemotherapy resistance is still unclear [10].

Among the various chemotherapy regimens for GC, oxaliplatin (OXA) is a basic drug for chemotherapy in GC patients [11]. Oxaliplatin belongs to the third generation of platinum antitumor drugs, which have no toxicity overlap with most chemotherapy drugs used and especially have a low incidence of blood and gastrointestinal toxicity [12]. The 2016 National Comprehensive Cancer Network (NCCN) guidelines established regimens containing oxaliplatin as the first-line chemotherapy regimen for the treatment of gastrointestinal malignant tumors [13]. At present, oxaliplatin is mainly used clinically to treat various malignant tumors of the digestive system, such as GC, liver cancer, and colorectal cancer [14, 15]. However, many patients with gastrointestinal tumors show resistance to oxaliplatin, leading to treatment failure and poor outcomes [16]. Some studies have explored the potential molecular mechanism of oxaliplatin resistance, including upregulation of ATP-binding cassette transporters (promoting efflux of chemotherapy drugs), oxaliplatin-induced DNA damage repair, enhanced resistance to apoptosis and autophagy, DNA methylation, and histone modification, but thus far, no effective molecule has been found to reverse the resistance to oxaliplatin [17].

The development of quantitative proteomics provides a possible method for us to discover key oxaliplatin-resistant molecules in GC patients [18]. In this study, we used this method and found that cellular retinoic acid binding protein 2 (CRABP2) was the most significantly upregulated protein in the tumor tissues of chemotherapy-resistant patients. CRABP2 belongs to the family of retinoic acid binding proteins and is the major regulator in the process of retinoic acid metabolism [19]. CRABP2 transports retinoic acid to the retinoic acid receptor in the nucleus and regulates cell proliferation, apoptosis, invasion, and migration [20]. It has been reported that the abnormal expression of CRABP2 is closely related to the development of neuroblastoma, Wilms tumor, head and neck squamous cell carcinoma, and non-small-cell lung cancer [21–23]. CRABP2 promotes the invasion and metastasis of pancreatic cancer cells, and inhibiting the expression of CRABP2 can inhibit the migration of cancer cells [24]. In esophageal squamous cell carcinoma, Koreeda et al. found that downregulating CRABP2 inhibits cell proliferation and induces cell apoptosis [25]. In addition, CRABP2 regulates the metastasis and invasion of breast cancer through the Hippo pathway [26].

In this study, we investigated the OXA resistance-related protein CRABP2, which was significantly upregulated in both chemoresistant GC tissues and cell lines. Moreover, the expression of CRABP2 was increased in the GC tumor tissues of our cohort and the TCGA database. We performed IHC staining of CRABP2 in 488 GC cases and confirmed that the expression of CRABP2 was significantly associated with the OS of GC patients. These results all implied that CRABP2 may play an important role in the chemoresistance of GC. To verify the molecular functions of CRABP2 in GC cells, we overexpressed CRABP2 in normal GC cells and knocked down CRABP2 in both OXA-resistant and normal GC cells. Then, we performed a series of cell functional experiments in the presence or absence of OXA in two GC cell lines. The results of these experiments all showed that CRABP2 promotes cell proliferation and inhibits cell apoptosis in GC cells, especially in the presence of OXA. Most chemotherapeutic drugs have anticancer effects by inhibiting cell proliferation and promoting cell apoptosis [27]. Thus, these results support the hypothesis that CRABP2 is an important molecule in the OXA resistance of GC.

The apoptotic cascade triggered by OXA is characterized by the translocation of BAX to mitochondria, the release of cytochrome c into the cytoplasm, and the activation of caspase 3 [28]. By the Co-IP assay, we identified the interacting proteins of CRABP2 in GC. The results of the GST pulldown assay verified that CRABP2 could directly interact with BAX and PARKIN in GC. The BAX protein belongs to the BCL-2 protein family, which is a proapoptotic effector [29]. It controls the mitochondrial apoptotic pathway, which is engaged by physiological stimuli or by cytotoxic drugs, including OXA. The interaction between BCL-2 pro- and anti-apoptotic family members sets the apoptotic threshold that determines the life/death decision: once the balance is tipped toward the formation of BAX oligomers, the cell is committed to suicide [30]. Apoptosis signaling and caspase activation result in a conformational change in the normally monomeric BAX, which exposes the BH3 domain of BAX, leading to dimerization and resistance to ubiquitin degradation [31]. BAX then translocates into the mitochondria, resulting in the release of proapoptotic mitochondrial factors such as cytochrome c and second mitochondria-derived activator of caspase. This results in the activation of caspase-3 and formation of the apoptosome [32].

Ubiquitination is a common form of protein degradation, and the PARKIN protein is a highly effective product that activates E3 ubiquitin-protein ligase activity [33]. Our results suggested that CRABP2 binds to BAX and PARKIN. Thus, we assumed that CRABP2 can promote the degradation of BAX. Our study proved that CRABP2 promotes the binding of BAX and PARKIN, leading to the ubiquitination and degradation of BAX. This effect finally inhibited cell apoptosis and achieved OXA resistance in GC cells. Apoptosis induces a conformational change in BAX that inhibits proteasome degradation [34]. In nonapoptotic cells, BAX dimerization is inhibited because the hydrophobic C-terminus of BAX masks the BH3 domain [35]. This configuration is also more susceptible to proteasome degradation. After apoptosis signaling,
a caspase-dependent conformational change results in resistance to proteasome degradation and translocation of BAX to the mitochondria, which correlates to the release of cytochrome c that amplifies apoptosis signaling events \[36\]. BAX integrates into the outer mitochondrial membrane, leading to the release of cytochrome C and cell apoptosis \[37\]. Furthermore, to verify the OXA resistance mechanisms of CRABP2, we performed rescue experiments in vitro and in vivo. The results showed that CRABP2 promotes OXA resistance through the BAX-dependent cell apoptosis pathway. Then we performed in vitro and in vivo...
experiments to prove the role of PARKIN in oxaliplatin resistance (Supplementary Fig. 5). Finally, through the above experiments, we confirmed that the mechanism of CRABP2 involved in oxaliplatin resistance is to inhibit cell apoptosis through the degradation of BAX by PARKIN.

In this study, we also investigated the molecular mechanisms of abnormally high expression of CRABP2 in OXA-resistant GC. The results confirmed that CRABP2 was sensitive to methylated and hydroxymethylated modifications. The methylation level of OXA-resistant cells decreased, while the level of hydroxymethylation increased. We further confirmed that the activity of the hydroxymethylase TET1 was enhanced and that TET1 could be enriched in the promoter region of CRABP2. TET1 belongs to the ten eleven translocation (TET) family of proteins, which are important regulators of DNA methylation. TET proteins can oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which is the basis for the demethylation of TET proteins [38]. In our study, the hydroxymethylated ChIP assay confirmed that there is a hydroxymethylated modification in the promoter region of CRABP2. TET1 plays important roles in embryonic development, germ cell formation and bone marrow hematopoiesis [39]. In hepatocellular carcinoma, the upregulation of TET1 could drive cell growth through aberrant enhancer hydroxymethylation of HMGA2 [40]. TET1 has been reported to inhibit the progression of nonalcoholic fatty liver disease by hydroxymethylation of the PPARG promoter [41]. In this study, we proved the role of TET1 in oxaliplatin resistance through in vitro and in vivo experiments (Supplementary Fig. 6). The results of our study verified that the expression of CRABP2 is affected by TET1-mediated DNA hydroxymethylation in OXA-resistant GC.

To explore the value of CRABP2 as a potential therapeutic target, we established a patient-derived xenograft (PDX) model. We further constructed a small interfering RNA (siRNA) targeting CRABP2 and verified the interference efficiency. siRNA is a short fragment of 21–23 bp double-stranded RNA that can induce RNA interference [42]. Since siRNA drugs for cancer treatment entered clinical trials for the first time in 2008, siRNA is expected to become an effective treatment method for tumor treatment due to its specificity and high efficiency [43]. In this study, we constructed in vivo-grade siRNA injections using LIPID In Vivo Transfection Reagent (Altogen Biosystems) to ensure the interference efficiency of CRABP2 in vivo [44]. The results of the PDX model suggested that interference with CRABP2 reversed OXA resistance in vivo. These results reveal the potential of CRABP2 as a molecular therapeutic target in chemoresistant GC patients.

In conclusion, the results of our study show that increased expression of CRABP2 by TET1-mediated DNA hydroxymethylation in GC is related to OXA resistance and could be a poor prognostic factor in GC patients. In OXA-resistant GC cells, CRABP2 was found to promote the binding of BAX and PARKIN, leading to the ubiquitination and degradation of BAX and ultimately preventing the apoptosis of cells under OXA treatment. This article revealed the key role of CRABP2 in regulating OXA resistance, which could be a potential new target for reversing the chemoresistance of GC.

**MATERIALS AND METHODS**

**Patient samples and clinical data collection**

From 2017 to 2019, patients diagnosed with advanced GC who received neoadjuvant chemotherapy (NAC) at Qilu Hospital of Shandong University were enrolled in this study. All patients received the SOX regimen ([oxaliplatin + S-1 (tegafur gimeracil oteracil potassium capsule)]) (oxaliplatin 130 mg/m², intravenously, day 1; and S-1, 40–60 mg, twice a day, orally, days 1 to 14) for 2 to 4 cycles and were evaluated for response to treatment before surgery [45]. All patients received enhanced computed tomography (CT) before the first and after the last NAC. The chemotherapy response was evaluated following the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria [46]. Partial response (PR) was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on the study. Stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor an increase to qualify for PD [47]. The pathological features were evaluated according to the National Comprehensive Cancer Network (NCCN) tumor regression grading (TRG) score [48]. A response was defined as no evidence that the tumor had staged up and a TRG score of 0 to 3. We collected tumors and matched adjacent nontumor (nearby tissues that were greater than 5 cm away) tissues within 30 min after resection of the specimen. Each specimen was rinsed with sterile saline and cut into two pieces. One piece was formalin-fixed and paraffin-embedded for pathology examination. Another piece was restored in liquid nitrogen and then transferred to a −80 °C refrigerator and used for quantitative proteomics and western blotting. Then, based on a rigorous evaluation of radiological and pathological evidence, the cases were classified into two groups: chemotherapy sensitive (group PR, n = 5) and chemotherapy resistant (group SD, n = 5) (Supplementary Table 1) [49]. All patients received follow-up every 6 months from the date of surgery. All patients provided written informed consent before treatment and sample collection. This study was approved by the Ethics Committee of Qilu Hospital of Shandong University.

**Tandem mass tags (TMT) based quantitative proteomics**

Total protein extraction was carried out according to the flow of the protein extraction kit (Thermo Fisher, MA, USA). Total protein extraction was performed following the manufacturer’s protocols [50]. BSA standard protein solution was prepared according to the instructions of the Bradford protein quantitative kit, with gradient concentrations ranging from 0 to 0.5 g/L. Proteins were extracted, digested with trypsin, and labeled with TMT reagents. The pooled peptides were separated into 15 fractions using a C18 column (Waters BEH C18 4.6 × 250 mm, 5 μm) on a RigoL L3000 HPLC. A total of 120 μg of each protein sample was used. Then, 100 μL of 0.1 M TEAB buffer was added for reconstitution, 41 μL of acetonitrile-dissolved TMT labeling reagent was added, and the sample was mixed with shaking for 2 h at room temperature. Then, the reaction was stopped by adding 8% ammonia. All labeled samples were mixed with equal volumes, desalted, and lyophilized. For transition library construction, shotgun proteomics analyses were performed using an EASY-nLC™ 1200 UHPLC system (Thermo Fisher, MA, USA) coupled with a Q Exactive HF-X mass spectrometer (Thermo Fisher, MA, USA) operating in the data-dependent acquisition (DDA) mode. The resulting spectra from each run were searched separately against the database by the search engine Proteome Discoverer 2.2 (Thermo Fisher, MA, USA). The protein quantitation results were statistically analyzed by t test. The proteins whose quantitation was significantly different between the experimental and control groups (P < 0.05 and |log2FC| > 1 (ratio > 1 or ratio < 1 [fold change, FC]) were defined as differentially expressed proteins (DEPs).
RNA extraction and quantitative real-time PCR (qRT–PCR)
RNA was extracted from cultured cells and tumor tissues using the RNeasy Micro Kit (Qiagen, Hilden, Germany). Total RNA was reverse transcribed into cDNA with PrimeScript RT Master Mix (TaKaRa, otsu, Japan). SYBR green qRT–PCR was performed using PCR Master Mix (Life Technology, NY, USA). The expression of the target gene was determined relative to β-actin, and relative expression was calculated by the ΔΔCt method. The primer sequences for qRT–PCR used in this study are shown in Supplementary Table 4.

Cell culture and chemoresistant cell line induction
The human gastric cell lines AGS and HGC-27 were purchased from the China Center for Type Culture Collection (Shanghai, China). The cells were cultured...
were separated, and the expression of BAX was examined by western blotting. HGC-27 cells.

Overexpression in AGS/HGC-27 cells.

The results are expressed as the mean ± SD of three independent experiments.

HA were performed. After adding OXA to AGS/HGC-27 cells, the activities of caspase 9 (e) and caspase 12 (d) were detected. CRABP2 knockdown or overexpression were transfected with HA-labeled ubiquitinated plasmids of different sites, and Co-IP experiments of HA were performed. After adding OXA to AGS/HGC-27 cells, the activities of caspase 9 (c) and caspase 12 (d) were detected.

Affected OXA to AGS/HGC-27 cells, the expression of DNA damage/repair-related proteins was examined by western blotting. After AGS/HGC-27 cells were treated with OXA, the cytoplasm and mitochondria activities of caspase 9 were detected after CRABP2 knockdown/overexpression in AGS/HGC-27 cells. The expression of CC3 was examined after CRABP2 knockdown/overexpression and OXA added to AGS/HGC-27 cells. After adding OXA to AGS/HGC-27 cells and knocking down/overexpressing CRABP2, the expression of DNA damage/repair-related proteins was examined by western blotting.

CRABP2 promoted chemoresistance by regulating ubiquitination degradation of Bax. CRABP2 knockdown or overexpression were transfected with HA-labeled ubiquitinated plasmids of different sites, and Co-IP experiments of HA were performed. After adding OXA to AGS/HGC-27 cells, the activities of caspase 9 (c) and caspase 12 (d) were detected. After adding OXA to AGS/HGC-27 cells, the expression of DNA damage/repair-related proteins was examined by western blotting. After AGS/HGC-27 cells were treated with OXA, the cytoplasm and mitochondria activities of caspase 9 were detected after CRABP2 knockdown/overexpression in AGS/HGC-27 cells. The expression of CC3 was examined after CRABP2 knockdown/overexpression and OXA added to AGS/HGC-27 cells. After adding OXA to AGS/HGC-27 cells and knocking down/overexpressing CRABP2, the expression of DNA damage/repair-related proteins was examined by western blotting.

activity changes in caspase 9 and caspase 12 were detected. After knockdown or overexpression of CRABP2 in cells and treatment with OXA, the activity changes in caspase 9 and caspase 12 were detected.

For the apoptosis assay, cells cultured in 96-well plates were collected, and then 5 μl of Annexin V-FITC (Sigma-Aldrich, MO, USA) and 5 μl of propidium iodide (PI) staining (50 μg/ml, Sigma-Aldrich, MO, USA) were added. Cell apoptosis was analyzed on a flow cytometer (Thermo Fisher, MA, USA).

Activity detection of caspase 9 and caspase 12

The activity of caspase 9/12 were detected following the instructions of different drug concentrations. GraphPad Prism 8 software (USA) was used to draw the curves and calculate the 50% inhibitory concentration (IC50) value.

Flow cytometry assay

For the apoptosis assay, cells cultured in 96-well plates were collected, and then 5 μl of Annexin V-FITC (Sigma-Aldrich, MO, USA) and 5 μl of propidium iodide (PI) staining (50 μg/ml, Sigma-Aldrich, MO, USA) were added. Cell apoptosis was analyzed on a flow cytometer (Thermo Fisher, MA, USA).

Activity of caspase 9 and caspase 12

The activities of caspase 9/12 were detected following the instructions of different drug concentrations. GraphPad Prism 8 software (USA) was used to draw the curves and calculate the 50% inhibitory concentration (IC50) value.

Cell viability assay

The cells were seeded in a 96-well plate and cultured for 24 h, and then drugs were added after the cells adhered. Different concentrations of OXA were added to the wells of plates according to the experimental requirements. Each concentration was assessed in 3 experimental replicates. An adjustment well without cells and a control well without drugs were used as a control. After being cultured for 48 h, the culture medium was discarded, 100 μl of fresh complete medium was added to each well, and then washed three times with PBS. Next, the slides were incubated with 4% parafomaldehyde for 15 min and rinsed three times with PBS. The cells were neutralized with 5% glycine for 5 min and penetrated with 5% Triton X-100 for 15 min. The slides were incubated with anti-goat serum for 1 h and then washed three times with PBS.

Immunofluorescence

Immunostained was performed as standard protocol. Briefly, AGS cells were seeded in 24-well slides. Then, the cells were fixed with 4% paraformaldehyde for 15 min and rinsed three times with PBS. The cells were neutralized with 5% glycine for 5 min and penetrated with 5% Triton X-100 for 15 min. The slides were incubated with anti-goat serum for 1 h and then washed three times with PBS.
with a mouse-derived CRABP2 (ProteinTech, Cat. #66468-1-Ig) primary antibody/ rabbit-derived BAX (ProteinTech, Cat. #50599-2-lg) primary antibody/ mouse-derived BAX (ProteinTech, Cat. #60267-1-Ig) primary antibody/rabbit-derived PARKIN (ProteinTech, Cat. #14060-1-AP) primary antibody overnight. The rabbit-derived fluorescent secondary antibody with red fluorescence and the mouse-derived fluorescent secondary antibody with green fluorescence were incubated at room temperature for 1 h and washed three times with PBS. The slides were stained with DAPI (Thermo Fisher, MA, USA) for 5 min and washed three times with PBS. Then, the slides were transferred to carrier glass, and the slides were photographed by confocal microscopy LSM980 (Carl Zeiss AG, Oberko-chen, Germany).

Fig. 5  CRABP2 promoted oxaliplatin resistance through the BAX-dependent cell apoptosis pathway. a After knocking down CRABP2/ BAX and adding OXA (concentration: AGS 0.2 μM, HGC-27 0.4 μM), the percentage of apoptotic cells was examined by flow cytometry. b After knocking down CRABP2/ BAX and adding OXA (concentration: AGS 0.2 μM, HGC-27 0.4 μM), the activity of cleaved caspase 9 was examined. c After knocking down CRABP2/ BAX and adding OXA (concentration: AGS 0.2 μM, HGC-27 0.4 μM), the expression of cleaved caspase 3/BAX/CRABP2 was examined by western blotting. d Schematic diagram of the experimental procedures of the cell-derived xenograft model in nude mice. e Photo showing tumor formation in the four groups of nude mice. Tumor weight (f) and tumor volumes (g) of four groups of nude mice. h The expression of CRABP2 and BAX in tumors from four groups of nude mice by western blotting. i HE and CRABP2 IHC staining of tumors in four groups of nude mice. All experiments were performed in three replicates. *P < 0.05, **P < 0.01, ***P < 0.001.
Fig. 6  TET1-mediated DNA hydroxymethylation expedited the expression of CRABP2. a After adding SAZ, Bobcat339, DZNep, TSA, or SAHA to AGS and HGC-27 cells, the mRNA expression changes in CRABP2 were detected. The methylation (b) and hydroxymethylation (c) levels of OXA-resistant GC cells and parental GC cells were examined. d The expression and activity of DNA methylase, demethylase, and hydroxymethylase from OXA-resistant and parental GC cells were examined by western blotting. e The activity of hydroxymethylase TET1 was detected in OXA-resistant GC cells and parental GC cells. f Schematic diagram of the predicted and designed methylation sites in the promoter region of CRABP2. g ChIP experiments using a TET1 antibody were performed in OXA-resistant GC cells. h Hydroxymethylated ChIP assays were performed in OXA-resistant GC cells. After knocking down or overexpressing TET1 in OXA-resistant GC cells, the expression of CRABP2 was examined by qRT–PCR (i) and western blotting (j). *P < 0.05, **P < 0.01, ***P < 0.001, ns not significant.
Fig. 7  Interference with CRABP2 reversed oxaliplatin resistance in GC in vivo. a Schematic diagram of the patient-derived xenograft model of GC. b Photos of different tumor formations in the two groups of NOD-SCID mice. Tumor weight (c) and tumor volume (d) measurement in the two groups of mice. e Expression of CRABP2 and BAX in tumors from the two groups of mice, as determined by western blotting. f HE staining and CRABP2 staining of tumor slides from the two groups of mice. g Under normal physiological conditions, the synthesis and degradation of Bax in the cytoplasm are in equilibrium. When cells are treated with oxaliplatin, Bax integrates into the outer mitochondrial membrane, leading to the release of cytochrome C and cell apoptosis. In chemoresistant GC cells, in which the expression of CRABP2 in the cell is at a high level, CRABP2 can promote the ubiquitination degradation of Bax by combining Bax and Parkin, ultimately allowing the cells to survive. *P < 0.05, **P < 0.01, ***P < 0.001.
Glutathione S transferase (GST) pull-down assay
To study the interaction between CRABP2 and BAX/Parkin, we cultured *Escherichia coli* (E. coli) B21 transformed with plasmid encoding GST or GST-CRABP2 fusion protein overnight at 37°C to purify GST or GST-CRABP2 fusion protein. The plasmids used in this experiment were constructed by the Biosune Biotechnology Co., Ltd. (Shanghai, China). Then, isopropyl-β-D-thiogalactoside was added and incubated for 4 h. Lyse the bacteria with PBST buffer (10 mM sodium phosphate, 2 mM potassium phosphate, 140 mM NaCl, 3 mM KCl, 0.1% Tween 20). Ultrasound was then used to destroy the cell wall. Then, 100 μl of 20% Triton X-100 was added and placed on ice for 30 min. The bacterial lysate supernatant was incubated on ice for 30 min. The bacterial lysate supernatant was incubated with glutathione agarose (Thermo Fisher, USA) for 30 min at 4°C to isolate the GST or GST-CRABP2 fusion protein. Resuspend the magnetic beads bound to the purified GST or GST-CRABP2 fusion protein. At the same time, E. coli B21 transformed with GST-BAX/Parkin fusion protein guided by 6xHis was cultured overnight at 37°C. The subsequent steps were the same as those for studying the GST or GST-CRABP2 fusion protein. For GST pull-down, the empty carrier protein, GST-BAX/Parkin fusion protein, and the supernatant of the cell lysate were incubated with the purified GST-CRABP2 fusion protein (50 μg/ml) at 4°C for 4 h. The incubation was terminated by adding agarose beads and washing 3 times with PBST buffer. The BAX/Parkin protein bound to the CRABP2-GST fusion protein was analyzed by western blotting.

Nude mice xenograft assays
All animal experiments were performed humanely and in compliance with the protocol reviewed by the Ethics Committee of Qilu Hospital of Shandong University. Four-week-old male BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). For the cell-derived xenograft (CDX) model, the mice were randomly divided into three groups: 1 × 10^6 HGC-27 cells infected with negative control lentivirus (group NC, 20 mice), CRABP2 overexpression lentivirus (group oe-Crabp2, 10 mice) or CRABP2 plus BAX overexpression lentivirus (group oe-Crabp2 + oe-Bax, 10 mice) were injected into the right axilla of nude mice. Four weeks after the injection, the growth of tumors was observed. Then, the mice in the NC group were randomly divided into two groups (10 mice in each group) and intraperitoneally injected with the same amount (5 mg/kg) of PBS or PBS-dissolved oxaliplatin into three times per week. The mice in the other two groups were given the same amount of PBS-dissolved oxaliplatin three times per week.

To study the interaction between CRABP2 and BAX/Parkin, we cultured E. coli B21 transformed with GST-BAX/Parkin fusion protein guided by 6xHis was cultured overnight at 37°C. The subsequent steps were the same as those for studying the GST or GST-CRABP2 fusion protein. For GST pulldown, the empty carrier protein, GST-BAX/Parkin fusion protein, and the supernatant of the cell lysate were incubated with the purified GST-CRABP2 fusion protein (50 μg/ml) at 4°C for 4 h. The incubation was terminated by adding agarose beads and washing 3 times with PBST buffer. The BAX/Parkin protein bound to the CRABP2-GST fusion protein was analyzed by western blotting.

Quantitative analysis of genomic methylation and hydroxymethylation
The genomic DNA of the AGS and HGC-27 parental and OXA-resistant cells was extracted by the TIANamp Genomic DNA Kit (TIANGEN Biotech, Beijing, China). The parental and OXA-resistant cells were crosslinked with 1% formaldehyde for 10 sec, followed by a 30-s pause, which was repeated 4 times with 48 W of UV light. The fixed cells were washed twice with cold PBS buffer to obtain total protein. The protein was separated on a 10% SDS-PAGE gel. Western blotting was used to determine the expression of CRABP2, BAX, and PARKIN. The membrane was incubated with primary antibody overnight at 4°C and then incubated with the secondary antibody (1:15,000, GE Healthcare, Cambridge, UK) for 1 h, the membrane was incubated with primary antibody overnight at 4°C and then incubated with the secondary antibody (1:15,000, GE Healthcare, Cambridge, UK) for 1 h at room temperature. Then, visualization was performed with ECL chemiluminescence reagent (Merck Healthcare, Cambridge, UK) for 1 h at room temperature. Then, the tissue blocks were transplanted subcutaneously into the right axilla of twenty NOD-SCID (Non-Obese Diabetes-Server Combined Immune Deficiency) mice. After four weeks, when the xenografts reached approximately 100 mm³, all the mice were intraperitoneally injected with saline-dissolved oxaliplatin (5 mg/kg/mouse; 3 times/week). Eight weeks later, the largest xenografts (indicating the most resistant to OXA) were isolated and cut into 1 mm³ tissue blocks. Then, the tissue blocks were transplanted subcutaneously into the right axilla of another twenty NOD-SCID mice for the second-generation PDX model (54). After four weeks, when the xenografts reached nearly 100 mm³, the mice were randomly divided into two groups. Then, we constructed in vivo-grade siRNA injections using LIPID In Vivo Transfection Reagent (Altogen Biosystems, NV, USA). All mice were treated with oxaliplatin using the above scheme, and each xenograft was intraperitoneally injected with normal saline-dissolved oxaliplatin (5 mg/kg/mouse; 3 times/week) and locally injected with 5 nmol siRNA (si-Crabp2, Group 1) or its negative control (si-NC, Group 2) three times per week. The tumors were measured every three days and recorded as L and W, respectively. The tumor volume was calculated as follows: V (mm³) = L×W²×0.5. After all treatments were administered, the mice were euthanized, and the xenografts were removed. Half of the tumors were frozen in liquid nitrogen, and total proteins were extracted following the abovementioned method. The expression of CRABP2 and BAX in tumors from different groups was examined by western blotting. The other half of the tumors were immersed in formalin and embedded in paraffin, followed by hematoxylin-eosin (HE) staining to confirm the pathological diagnosis, and the expression of CRABP2 was detected by IHC.

Western blotting
Cells were first lysed (Solarbio, Beijing, China) and then denatured in SDS buffer to obtain total protein. The protein was separated on a 10% SDS-polyacrylamide gel (30 μg per lane) and transferred to a PVDF membrane (Merck Millipore, MA, USA). After blocking in 5% skim milk for 1 h, the membrane was incubated with primary antibody overnight at 4°C and then incubated with the secondary antibody (1:15,000, GE Healthcare, Cambridge, UK) for 1 h at room temperature. Then, visualization was performed with ECL chemiluminescence reagent (Merck Millipore, MA, USA).

The antibodies used in this study were as follows: CRABP2 (1:1,000, Proteintech, Cat. # 10225-1-AP), BAX (1:1,000, Abcam, ab32530), BCL-2 (1:1,000, Abcam, ab32214), cleaved caspase-3 (1:1,000, Abcam, ab32240), PARKIN (1:1,000, Proteintech, Cat. # 14060-1-AP), ATR (1:1,000, Abcam, ab2905), p-ATR (1:1,000, Abcam, ab178407), ATM (1:1,000, Abcam, ab32420), p-ATM (1:1,000, Abcam, ab81292), P53 (1:1,000, Abcam, ab32389), p-P53 (1:1,000, Abcam, ab32389), TET1 (1:1,000, Abcam, ab272900), DNMT3A (1:1,000, Abcam, ab186470), DNMT3B (1:1,000, Abcam, ab2851), P62 (1:1,000, Proteintech, Cat. # 18420-1-AP), TOMM40 (1:1,000, Abcam, ab185543), α-tubulin (1:5,000, Abcam, ab7291), β-actin (1:5,000, Proteintech, Cat. # 66009-1-lg), GAPDH (1:20,000, Proteintech, Cat. # 60004-1-lg).

Statistical analysis
The Cancer Genome Atlas (TCGA) data were downloaded from The Cancer Genome Atlas-Stomach Adenocarcinoma (TCGA-STAT) server through client software, and then the data were extracted and analyzed. We downloaded the RNAseq data of gastric cancer samples from TCGA, converted the data into TPM (transcripts per million reads) and performed log2 transformation. Because the sample distribution did not conform to the normal distribution, we used the Mann–Whitney U test (Wilcoxon rank sum test). Outlier values [median±2 interquartile range (IQR)] and extreme values (median ± 3.5 IQR) were excluded. All enrolled cases were staged according to the 7th edition American Joint Committee on Cancer (AJCC) staging system. Patient demographic
information, histopathological information, pathological tumor stage (pT stage), pathological lymph node stage (pN stage), pathological tumor-lymph node-metastasis stage (pTNM stage), treatment details (including chemotherapy details, surgical types), and survival data were collected. Overall survival (OS) was defined as the time interval from the date of initial surgical resection to the date of the last known contact or death. All values are expressed as the mean ± standard deviation (SD). SPSS 20.0 (IBM, USA) and GraphPad Prism 8.0 (GraphPad Software, USA) software were used to analyze the data and make graphs. The correlation between CRABP2 and clinicopathological characteristics was assessed by χ² or Fisher’s test. The Kaplan–Meier method was used to analyze the survival curves, and the log-rank test was used to compare the statistical significance. Important variables in univariate survival analysis were included in the Cox proportional hazards regression model. The t test was used to compare two independent groups, and one-way analysis of variance was used to compare multiple groups. P < 0.05 was considered statistically significant.

DATA AVAILABILITY

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, et al. Changing cancer survival in China during 2003−15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555–e67.
3. Noh SH, Park SR, Yang HK, Chung HC, Chung UJ, Kim SW, et al. Adjuvant capcitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.
4. Martinez-Balibre E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L, et al. Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. Mol Cancer Ther. 2015;14:1767–76.
5. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264–79.
6. Liu J, Zhang C, Wu H, Sun XX, Li Y, Huang S, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. J Clin Invest. 2020;130:3253–69.
7. Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura K, Katai H, et al. Gastric cancer with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492–502.
8. Xu Z, Chen L, Xiao Z, Zhu Y, Jiang H, Jin Y, et al. Potentiation of the anticancer effect of doxorubicin drug-resistant gastric cancer cells by thapsigargin. Autophagy. 2020;16:419–25.
9. Ni B, Ma Q, Li B, Zhao L, Zhu Y, et al. Phenylarsine oxide induces apoptosis in cancer cells by ubiquitin. Autophagy. 2014;10:1893–94.
10. Yamaguchi H, Bhalla K, Wang HG. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/htrA2 release from mitochondria. Cancer Res. 2003;63:1483–9.
11. Roth W, Reed JC. Apoptosis and cancer: when BAX is TRAILing away. Nat Med. 2000;6:216–8.
12. Zhang HG, Wang J, Yang X, Hsu HC, Mourtz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009–15.
13. Yan C, Gong L, Chen L, Xu M, Abou-Hamdan H, Tang M, et al. PHB2 (prohibitin 2) promotes PINK1–PRKN/Parkin-dependent mitophagy by the PARL-PIGAM5-PINK1 axis. Autophagy. 2020;16:419–34.
14. Ni B, Ma Q, Li B, Zhao L, Liu Y, Zhu Y, et al. Phenylarsine oxide induces apoptosis in Bax- and Bak-deficient cells through upregulation of Bim. Clin Cancer Res. 2012;18:140–51.
15. Satomi D, Takiguchi N, Koda K, Oda K, Suzuki H, Yasutomi J, et al. Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int J Oncol. 2002;20:167–71.
16. Song S, Min H, Niu M, Wang L, Wu Y, Zhang B, et al. S1PR1 predicts patient survival and promotes chemotherapy drug resistance in gastric cancer cells through STAT3 constitutive activation. EBioMedicine 2018;37:168–76.
17. Low HB, Wong ZL, Wu B, Kong LR, Png CW, Cho YL, et al. DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death. Nat Commun. 2021;12:2284.
18. Poole CJ, Lodhi A, Choi JH, van Riggelen J, MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL. Epigenetics Chromatin. 2019;12:41.
19. Wu J, Li H, Shi M, Zhu Y, Ma Y, Zhong Y, et al. TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/beta-catenin signaling pathway to suppress EMT in pancreatic tumor cells. J Exp Clin Cancer Res. 2019;38:348.
20. Shirai K, Nagae G, Seki M, Kudo Y, Kamio A, Hayashi A, et al. TET1 upregulation in hepatocellular carcinoma. Cancer Sci. 2021;112:2855–69.
21. Wang J, Zhang Y, Zhao Q, Sheng Y, Wang J, Ma Y, et al. TET1 promotes fatty acid oxidation and inhibits NAFLD progression by hydroxymethylation of PPARα promoter. Nutr Metab (Lond). 2020;17:46.
22. Osborn MF, Khvorova A. Improving siRNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 2018;28:128–36.
23. Biscans A, Coles A, Haraszt R, Echeverria D, Hassler M, Osborn M, et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res. 2019;47:1082–96.
AUTHOR CONTRIBUTIONS
QH and GP designed this study and experiments. TXL, LYH, and JXZ performed the experiments. TXL and HZY analyzed the data and wrote the manuscript. SGR and HQS reviewed the manuscript and supervised the study. All authors contributed to experimental design and data analysis. The authors read and approved the final manuscript.

FUNDING
This study was supported by grants from the Natural Science Foundation of Shandong Province [No. ZR2021MH344, and ZR2020QH224], the China Postdoctoral Science Foundation [No. 2019M652393], and the National Natural Science Foundation of China [No. 82203634]. The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data and writing of this manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study was approved by the Ethics Committee of the Qilu Hospital of Shandong University. The study was performed in accordance with the Declaration of Helsinki.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-05299-2.

Correspondence and requests for materials should be addressed to Hui Qu.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022